Sanofi-aventis has announced results from three studies evaluating Eloxatin (oxaliplatin injection) in various gastrointestinal tumor types (colorectal, pancreatic and gastric cancers).

Final analysis of TREE-study demonstrates that Eloxatin-based chemotherapy combined with bevacizumab provided significant improvement in overall survival (OS) for patients with advanced colorectal cancer.

In the TREE-study, two successive cohorts (TREE-1 and TREE-2) were investigated. The TREE-1 study contained three arms, evaluating Eloxatin combined with three different ways to deliver fluoropyrimidine chemotherapy (intravenous infusion, intravenous bolus and oral). TREE-2 evaluated the same three regimens in combination with the vascular epithelial growth factor inhibitor bevacizumab. The two cohorts of patients were included from the same centers and investigators, and the inclusion and exclusion criteria, as well as the base cytotoxic chemotherapy regimens were identical in each cohort.